Recent Research on Mesothelioma
A special issue of Cancers (ISSN 2072-6694). This special issue belongs to the section "Cancer Therapy".
Deadline for manuscript submissions: closed (20 January 2024) | Viewed by 48701
Special Issue Editors
Interests: oesophageal cancer; lung cancer; malignant mesothelioma of the pleura; benign thoracic conditions
Interests: malignant pleural mesothelioma; non-small cell lung cancer; malignant peritoneal mesothelioma; oesophageal cancer; patient-reported outcome research; translational research; benign thoracic conditions
Special Issue Information
Dear Colleagues,
This Special Issue is about malignant mesothelioma, an aggressive cancer type with grim prognosis. Work-related asbestos exposure is the main cause of this disease. Despite the decrease in the use of asbestos and its known potent carcinogenicity, there are no clear signs of attenuation in centers that treat this disease. The global estimation of the annual deaths related to mesothelioma is 38,400 individuals, making this a global health issue.
With the advent of personalized cancer medicine, there have been recent promising results obtained by maximizing tri-modality therapy (chemotherapy, radiation therapy, and surgery), CAR T-cell therapy, and immune checkpoint inhibitors to name few. We have also gained new insight into the pathogenesis of this disease.
We invite researchers to submit manuscripts for this Special Issue in every aspect of mesothelioma research (basic science, translational, and clinical), as well as the impact and causes of mesothelioma, as the nature of this disease has changed from heavy industrial asbestos exposure to more latent exposure.
Dr. Jari Räsänen
Dr. Ilkka Ilonen
Guest Editors
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Cancers is an international peer-reviewed open access semimonthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- malignant pleural mesothelioma
- malignant peritoneal mesothelioma
- translational research
- clinical trials
- biomarkers
- targeted therapy
- multimodal therapy
- epidemiology and outcome research